Tag: viral vectors and plasmid DNA market share

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Viral Vectors And Plasmid DNA Market Forecast: What Value Will The Market Reach By 2030?

The viral vectors and plasmid dna market has experienced strong expansion in recent years. It is anticipated to increase from $1.38 billion in 2025 to $1.47 billion in 2026, at a compound annual growth rate (CAGR) of 6.2%. This market growth in the past can be attributed to the limited availability of viral vectors, reliance on research-grade plasmid dna, expanding gene therapy pipelines, growing biopharmaceutical R&D activities, and the adoption of conventional viral vector platforms.

The viral vectors and plasmid dna market size is anticipated to experience substantial expansion in the coming years. It is projected to reach $1.89 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This projected growth during the forecast period is attributable to several factors, including the advancement of clinical-grade and GMP plasmid DNA, the broader application of viral vectors in treating cancer and infectious diseases, increasing investments in gene therapy, the escalating demand for immunotherapy solutions, and the integration of new vector platforms like AAV and lentiviral vectors. Key trends anticipated during this period encompass the increasing utilization of plasmid DNA and viral vectors in gene therapy, the diversification of viral vector platforms for treating cancer and genetic disorders, a rise in GMP-grade plasmid DNA production for clinical uses, intensified research into innovative adeno-associated and lentiviral vectors, and the incorporation of plasmid DNA and viral vectors into immunotherapy and vaccine development efforts.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=51475046&type=smp&name=Viral%20Vectors%20And%20Plasmid%20DNA%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Viral Vectors And Plasmid DNA Market Growth Drivers: What’s Behind The Acceleration?

The rising occurrence of tuberculosis cases is projected to stimulate growth in the viral vector and plasmid DNA market moving forward. Tuberculosis (TB) is a highly infectious and potentially serious illness caused by bacteria, primarily impacting the lungs but also capable of affecting other body parts. Plasmid DNA vaccines have been employed to deliver microbial antigen-coding genes specifically for tuberculosis. These vaccines are customizable to express particular antigens of Mycobacterium tuberculosis, the bacterium responsible for the disease, and are administered via intramuscular injection. For instance, data from February 2024, released by GOV.UK, a UK-based government department, revealed that tuberculosis (TB) cases in England saw a 10.7% increase in 2023, climbing from 4,380 in 2022 to 4,850. Therefore, the escalating incidence of tuberculosis cases is significantly driving the expansion of the viral vector and plasmid DNA market.

Viral Vectors And Plasmid DNA Market Segmentation And Category Overview

The viral vectors and plasmid dna market covered in this report is segmented –

1) By Product: Plasmid DNA, Viral Vectors

2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases

3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications

4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies

Subsegments:

1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA

2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors

Viral Vectors And Plasmid DNA Market Trends: What’s Defining The Industry’s Next Phase?

Companies operating within the viral vectors and plasmid DNA market are intensifying their efforts to introduce novel products, such as helper plasmids, to establish a competitive edge. A helper plasmid is a form of plasmid DNA used in the creation of viral vectors, including adeno-associated viral vectors (AAV), which are commonly applied in gene therapy. As an illustration, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical company, launched off-the-shelf pHelper, a helper plasmid aimed at accelerating the process from initial discovery through commercial production of adeno-associated virus (AAV)-based gene therapy programs and ensuring secure supplies. This latest offering, part of a broad spectrum of contract development and manufacturing organization (CDMO) goods and services, is designed to safeguard viral vector packaging in cell and gene therapy operations and streamline complex supply chains.

Viral Vectors And Plasmid DNA Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, Каnеkа Соrроrаtіоn, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene

View The Full Viral Vectors And Plasmid DNA Market Report:

https://thebusinessresearchcompany.com/report/Viral-Vectors-and-Plasmid-DNA-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Viral Vectors And Plasmid DNA Market Top Region By Revenue And Market Share

North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Viral Vectors And Plasmid DNA Market Size And Revenue Forecast Through 2030

The viral vectors and plasmid DNA market has experienced notable expansion in recent years. Projections indicate an increase from $1.38 billion in 2025 to $1.47 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.2%. This historic growth has been driven by factors such as the constrained supply of viral vectors, a dependence on research-grade plasmid DNA, a rising number of gene therapy development programs, heightened research and development efforts within the biopharmaceutical sector, and the widespread use of established viral vector platforms.

The market for viral vectors and plasmid DNA is forecast to experience significant growth in the coming years, with projections indicating a rise to $1.89 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period is driven by factors including the creation of clinical-grade and GMP-compliant plasmid DNA, the broadening of viral vector uses in oncology and infectious diseases, heightened investment in gene therapy, an increasing need for immunotherapeutic approaches, and the uptake of innovative vector systems like adeno-associated and lentiviral vectors. Key developments expected in this period encompass the growing utilization of plasmid DNA and viral vectors within gene therapy, the proliferation of viral vector platforms tailored for cancer and genetic disorder management, a surge in GMP-grade plasmid DNA output for clinical purposes, intensified investigation into novel adeno-associated and lentiviral vector technologies, and the incorporation of these elements into immunotherapy and vaccine development.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3245&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Viral Vectors And Plasmid DNA Market Development Factors: Which Trends Are Supporting Demand?

The viral vector and plasmid DNA market is expected to be driven forward by the rising number of tuberculosis cases. Tuberculosis (TB) is a contagious, severe infectious illness brought on by bacteria, mainly attacking the lungs but also capable of affecting other body parts. Plasmid DNA vaccines have been utilized to deliver genes coding for microbial antigens specific to TB. These vaccines can be tailored to express particular antigens from Mycobacterium tuberculosis, the pathogen responsible for the disease, and are typically given via intramuscular injection. For example, data from GOV.UK in February 2024, a UK government entity, revealed that TB cases in England climbed by 10.7% in 2023, increasing from 4,380 in 2022 to 4,850. Consequently, the growing TB incidence is fueling expansion in the viral vector and plasmid DNA market.

Viral Vectors And Plasmid DNA Market Segment Analysis And Revenue Opportunities

The viral vectors and plasmid dna market covered in this report is segmented –

1) By Product: Plasmid DNA, Viral Vectors

2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases

3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications

4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies

Subsegments:

1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA

2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors

Viral Vectors And Plasmid DNA Market Transformation Trends: Which Innovations Are Driving Change?

Key players in the viral vectors and plasmid DNA market are increasingly focusing on developing innovative solutions, such as helper plasmids, to strengthen their competitive position. A helper plasmid represents a type of plasmid DNA used in producing viral vectors like adeno-associated viral vectors (AAV), commonly applied in gene therapy. For example, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical firm, introduced its off-the-shelf pHelper helper plasmid, designed to accelerate processes from early discovery through commercial production of AAV-based gene therapy programs while ensuring supply security. As part of an expanding range of contract development and manufacturing organization (CDMO) offerings, these helper plasmids aim to protect viral vector packaging in cell and gene therapy operations and simplify complex supply chains. The production of adeno-associated viral vectors (AAV), frequently used in gene therapy, relies on helper plasmids to facilitate their creation.

Viral Vectors And Plasmid DNA Market Leading Players Shaping Industry Direction

Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k? ??r??r?t??n, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene

Access The Complete Viral Vectors And Plasmid DNA Market Report:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Viral Vectors And Plasmid DNA Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Viral Vectors And Plasmid DNA Market Between 2026 And 2030?

The viral vectors and plasmid dna market has seen significant expansion in recent years. Its value is expected to rise from $1.38 billion in 2025 to $1.47 billion in 2026, with a compound annual growth rate (CAGR) of 6.2%. Historically, this growth can be attributed to several factors including the restricted availability of viral vectors, reliance on research-grade plasmid dna, an increase in gene therapy pipelines, heightened biopharmaceutical research and development activities, and the adoption of conventional viral vector platforms.

The viral vectors and plasmid dna market size is forecast to show robust expansion over the next few years. It is expected to grow to $1.89 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.6%. This projected growth stems from factors such as the advancement of clinical-grade and GMP plasmid DNA, the wider application of viral vectors in treating cancer and infectious diseases, increased investment in gene therapy, a growing demand for immunotherapy solutions, and the adoption of innovative vector platforms like AAV and lentiviral vectors. Notable trends anticipated during this period include the increasing uptake of plasmid DNA and viral vectors in gene therapy, the broadening of viral vector platforms for cancer and genetic disorder treatments, a rise in GMP-grade plasmid DNA production for clinical uses, intensified research into novel adeno-associated and lentiviral vectors, and the incorporation of plasmid DNA and viral vectors in immunotherapy and vaccine development.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3245&type=smp

Which Core Factors Are Supporting The Expansion Of The Viral Vectors And Plasmid DNA Market?

The increasing prevalence of tuberculosis cases is anticipated to stimulate the expansion of the viral vector and plasmid DNA market in the future. Tuberculosis (TB) is a contagious and potentially serious bacterial infection that primarily affects the lungs but can also impact other bodily systems. Plasmid DNA vaccines are utilized to deliver microbial antigen-coding genes for tuberculosis. These vaccines can be engineered to express specific antigens from Mycobacterium tuberculosis, the bacterium responsible for the disease, and are administered via intramuscular injection. For instance, in February 2024, GOV.UK, a UK-based government department, reported that tuberculosis (TB) cases in England saw a 10.7% increase in 2023, rising from 4,380 in 2022 to 4,850. Consequently, the rising incidence of tuberculosis cases is propelling the growth of the viral vector and plasmid DNA market.

How Is The Viral Vectors And Plasmid DNA Market Distributed Across Key Segments?

The viral vectors and plasmid dna market covered in this report is segmented –

1) By Product: Plasmid DNA, Viral Vectors

2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases

3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications

4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies

Subsegments:

1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA

2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors

Which Trends Are Influencing The Expansion Of The Viral Vectors And Plasmid DNA Market?

Leading companies in the viral vectors and plasmid DNA market are intensifying their efforts to introduce innovative products, such as helper plasmids, to gain a competitive advantage. A helper plasmid is a form of plasmid DNA crucial for the production of viral vectors, including adeno-associated viral vectors (AAV), which are frequently used in gene therapy. For instance, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical company, launched its off-the-shelf pHelper. This helper plasmid aims to accelerate the entire process from initial discovery to the commercial manufacture of adeno-associated virus (AAV)-based gene therapy programs and to secure necessary supplies. As the newest addition to an extensive range of contract development and manufacturing organization (CDMO) products and services, helper plasmids are engineered to protect viral vector packaging during cell and gene therapy operations and to simplify complex supply chains. Helper plasmids are instrumental in creating adeno-associated viral vectors (AAV), which are commonly utilized in gene therapy.

Who Are The Companies Shaping The Viral Vectors And Plasmid DNA Market Landscape?

Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k? ??r??r?t??n, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene

Access The Complete Viral Vectors And Plasmid DNA Market Report:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Which Region Stands As The Largest Contributor To The Viral Vectors And Plasmid DNA Market?

North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Viral Vectors And Plasmid DNA Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3245&type=smp

Browse Through More Reports Similar to the Global Viral Vectors And Plasmid DNA Market 2026, By The Business Research Company

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Hospital Acquired Infections Testing Kits Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Viral Vectors And Plasmid DNA Market From 2026 To 2030?

The market for viral vectors and plasmid DNA has seen substantial expansion over recent years. Projections indicate it will rise from $1.38 billion in 2025 to $1.47 billion by 2026, achieving a compound annual growth rate (CAGR) of 6.2%. The market’s past expansion is traceable to several factors, including the constrained supply of viral vectors, dependence on research-grade plasmid DNA, the proliferation of gene therapy pipelines, heightened biopharmaceutical R&D efforts, and the utilization of conventional viral vector platforms.

The viral vectors and plasmid dna market size is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach $1.89 billion, showing a compound annual growth rate (CAGR) of 6.6%. Several factors will drive this growth during the projection period, including the advancement of clinical-grade and GMP plasmid DNA, the broader use of viral vector applications in cancer and infectious diseases, increased funding in gene therapy, a greater need for immunotherapy solutions, and the incorporation of novel vector platforms such as AAV and lentiviral vectors. Key trends expected during this forecast timeframe encompass the increasing utilization of plasmid DNA and viral vectors in gene therapy, the broadened scope of viral vector platforms for addressing cancer and genetic disorder treatments, an uptick in GMP-grade plasmid DNA production for clinical applications, intensified research into novel adeno-associated and lentiviral vectors, and the integration of plasmid DNA and viral vectors into immunotherapy and vaccine development.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3245&type=smp

What Key Drivers Are Fueling The Growth Of The Viral Vectors And Plasmid DNA Market?

The rising prevalence of tuberculosis cases is anticipated to drive forward the growth of the viral vector and plasmid DNA market. Tuberculosis (TB) is a transmissible and potentially severe infectious illness caused by bacteria, primarily impacting the lungs but capable of affecting other body parts. Plasmid DNA vaccines have been employed to introduce microbial antigen-coding genes for tuberculosis. These vaccines can be engineered to express specific antigens of Mycobacterium tuberculosis, the bacterium responsible for TB, and are administered via intramuscular injection. For instance, in February 2024, GOV.UK, a UK-based government department, disclosed that tuberculosis (TB) cases in England increased by 10.7% in 2023, climbing from 4,380 in 2022 to 4,850. Consequently, the increasing occurrence of tuberculosis cases is propelling the growth of the viral vector and plasmid DNA market.

How Is The Viral Vectors And Plasmid DNA Market Segmented Across Different Segment Categories?

The viral vectors and plasmid dna market covered in this report is segmented –

1) By Product: Plasmid DNA, Viral Vectors

2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases

3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications

4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies

Subsegments:

1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA

2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors

What Trends Are Affecting The Direction Of The Viral Vectors And Plasmid DNA Market?

Major companies operating in the viral vectors and plasmid DNA market are increasingly focusing on launching innovative products, such as helper plasmids, to gain a market advantage. A helper plasmid is a specific type of plasmid DNA integral to the production of viral vectors, including adeno-associated viral vectors (AAV), which are commonly employed in gene therapy. Illustratively, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical company, unveiled off-the-shelf pHelper. This helper plasmid aims to expedite the journey of adeno-associated virus (AAV)-based gene therapy programs from early research stages through to commercial manufacturing, concurrently securing necessary supplies. As a new offering among a wide array of contract development and manufacturing organization (CDMO) goods and services, these helper plasmids are designed to protect viral vector packaging in cell and gene therapy operations, streamline complex supply chains, and facilitate the creation of adeno-associated viral vectors (AAV) that are frequently utilized in gene therapy.

Which Organizations Play A Role In The Viral Vectors And Plasmid DNA Market Landscape?

Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k? ??r??r?t??n, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene

Get The Full Viral Vectors And Plasmid DNA Market Report:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Where Is The Viral Vectors And Plasmid DNA Market Primarily Concentrated By Region?

North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Viral Vectors And Plasmid DNA Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Browse Through More Reports Similar to the Global Viral Vectors And Plasmid DNA Market 2026, By The Business Research Company

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Hospital Acquired Infections Testing Kits Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Viral Vectors And Plasmid DNA Market Expected To Change Between 2026 And 2030?

The viral vectors and plasmid dna market size has exhibited strong growth in recent years. It is projected to expand from $1.38 billion in 2025 to $1.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.2%. The expansion seen in the historic period can be attributed to factors including limited availability of viral vectors, reliance on research-grade plasmid dna, increasing gene therapy pipelines, growing biopharmaceutical r&d activities, and the adoption of conventional viral vector platforms.

The viral vectors and plasmid dna market size is projected to experience substantial growth in the upcoming years, reaching $1.89 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period can be attributed to advancements in clinical-grade and GMP plasmid DNA, the broadening application of viral vectors in treating cancer and infectious diseases, increasing investment in gene therapy, a rising demand for immunotherapy solutions, and the embrace of novel vector platforms like AAV and lentiviral vectors. Significant trends expected in this period include the growing use of plasmid DNA and viral vectors in gene therapy, the extension of viral vector platforms for managing cancer and genetic disorders, an increase in GMP-grade plasmid DNA production for clinical purposes, enhanced research into new adeno-associated and lentiviral vectors, and the incorporation of plasmid DNA and viral vectors into the development of immunotherapies and vaccines.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3245&type=smp

What Underlying Factors Are Accelerating The Growth Of The Viral Vectors And Plasmid DNA Market?

The increasing occurrence of tuberculosis cases is expected to drive the expansion of the viral vector and plasmid DNA market in the future. Tuberculosis (TB) is a transmissible and potentially severe infectious disease caused by bacteria, primarily affecting the lungs but capable of impacting other bodily systems. Plasmid DNA vaccines are utilized to deliver microbial antigen-coding genes for tuberculosis. These vaccines can be formulated to express particular antigens of Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, and are administered through intramuscular injection. For instance, in February 2024, GOV.UK, a UK-based government department, reported that tuberculosis cases in England rose by 10.7% in 2023, increasing from 4,380 in 2022 to 4,850. Consequently, the rising incidence of tuberculosis cases is propelling the growth of the viral vector and plasmid DNA market.

How Is The Viral Vectors And Plasmid DNA Market Structured Across Different Segments?

The viral vectors and plasmid dna market covered in this report is segmented –

1) By Product: Plasmid DNA, Viral Vectors

2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases

3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications

4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies

Subsegments:

1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA

2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors

Which Trends Are Shaping The Future Of The Viral Vectors And Plasmid DNA Market?

Leading companies in the viral vectors and plasmid DNA market are intensifying their efforts to launch innovative products, such as helper plasmids, to gain a competitive advantage. A helper plasmid represents a form of plasmid DNA utilized in the production of viral vectors, including adeno-associated viral vectors (AAV), which are commonly employed in gene therapy. For instance, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical company, introduced off-the-shelf pHelper, a helper plasmid aimed at accelerating the process from early discovery through commercial manufacture of adeno-associated virus (AAV)-based gene therapy programs and ensuring secure supplies. As the newest offering among a broad spectrum of contract development and manufacturing organization (CDMO) goods and services, helper plasmids are engineered to protect viral vector packaging in cell and gene therapy operations and simplify intricate supply chains. Adeno-associated viral vectors (AAV), which are frequently utilized in gene therapy, are specifically created using these helper plasmids.

Which Major Players Dominate The Viral Vectors And Plasmid DNA Market?

Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, Каnеkа Соrроrаtіоn, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene

Read the full viral vectors and plasmid dna market report here:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Which Region Is Projected To Dominate The Viral Vectors And Plasmid DNA Market During The Forecast Period?

North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Viral Vectors And Plasmid DNA Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3245&type=smp

Browse Through More Reports Similar to the Global Viral Vectors And Plasmid DNA Market 2026, By The Business Research Company

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Hospital Acquired Infections Testing Kits Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the viral vectors and plasmid dna market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Viral Vectors And Plasmid DNA Market between 2026 and 2030?

The viral vectors and plasmid dna market size has seen strong growth in recent years. Projections indicate it will expand from $1.38 billion in 2025 to $1.47 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. The growth witnessed historically can be linked to several factors, including the constrained availability of viral vectors, the reliance on research-grade plasmid DNA, the expansion of gene therapy pipelines, increasing biopharmaceutical R&D activities, and the adoption of conventional viral vector platforms.

The viral vectors and plasmid dna market size is anticipated to experience substantial growth in the upcoming years. It is forecast to climb to $1.89 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.6%. This expansion during the projection period stems from the advancement of clinical-grade and GMP plasmid DNA, the wider application of viral vectors in combating cancer and infectious diseases, increasing financial input into gene therapy, a rising need for immunotherapy solutions, and the adoption of new vector platforms such as AAV and lentiviral vectors. Key developments during the forecast period include the increasing incorporation of plasmid DNA and viral vectors in gene therapy, the broadening scope of viral vector platforms for cancer and genetic disorder treatments, a rise in GMP-grade plasmid DNA production for clinical purposes, enhanced research into novel adeno-associated and lentiviral vectors, and the integration of plasmid DNA and viral vectors in immunotherapy and vaccine creation.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3245&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Viral Vectors And Plasmid DNA Market?

The growing number of tuberculosis (TB) infections is anticipated to boost the expansion of the viral vector and plasmid DNA market in the future. Tuberculosis (TB) is an infectious condition that is contagious, potentially severe, and caused by bacteria. While primarily impacting the lungs, it can also extend its effects to other bodily systems. Plasmid DNA vaccines have found application in delivering microbial antigen-coding genes for tuberculosis treatment. Such vaccines can be engineered to express particular antigens of Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, and are administrable via intramuscular injection. As an illustration, data from GOV.UK, a UK-based government department, revealed in February 2024 that tuberculosis (TB) cases in England saw a 10.7% increase in 2023, climbing from 4,380 in 2022 to 4,850. Consequently, the rising occurrence of tuberculosis cases is fueling the growth of the viral vector and plasmid DNA market.

How Is The Viral Vectors And Plasmid DNA Market Organized Into Various Segments?

The viral vectors and plasmid dna market covered in this report is segmented –

1) By Product: Plasmid DNA, Viral Vectors

2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases

3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications

4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies

Subsegments:

1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA

2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors

How Are Emerging Trends Affecting The Progression Of The Viral Vectors And Plasmid DNA Market?

Leading companies within the viral vectors and plasmid DNA market are increasingly focusing on introducing innovative products, such as helper plasmids, to gain a competitive edge. A helper plasmid is a form of plasmid DNA essential for the production of viral vectors, including adeno-associated viral vectors (AAV), commonly employed in gene therapy. For instance, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical company, launched its off-the-shelf pHelper. This helper plasmid aims to accelerate the process from early discovery to commercial manufacture for adeno-associated virus (AAV)-based gene therapy programs and ensure secure supplies. As the newest offering among a broad range of contract development and manufacturing organization (CDMO) goods and services, helper plasmids are designed to protect viral vector packaging in cell and gene therapy operations and streamline complex supply chains. Ultimately, adeno-associated viral vectors (AAV), which are frequently utilized in gene therapy, are indeed created using helper plasmids.

Who Are The Primary Competitors In The Global Viral Vectors And Plasmid DNA Market?

Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k? ??r??r?t??n, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Viral Vectors And Plasmid DNA Market?

North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Viral Vectors And Plasmid DNA Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3245&type=smp

Browse Through More Reports Similar to the Global Viral Vectors And Plasmid DNA Market 2026, By The Business Research Company

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Hospital Acquired Infections Testing Kits Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model